ADC Therapeutics (ADCT) Other Non-Current Assets (2019 - 2026)

ADC Therapeutics has disclosed Other Non-Current Assets across 8 years of filings, most recently posting $1.2 million for Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $1.2 million, up 7.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (up 7.14% YoY), and the FY2025 annual result was $1.2 million, up 4.82% from the prior year.
• Other Non-Current Assets came in at $1.2 million for Q1 2026 at ADC Therapeutics, up from $1.2 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $1.3 million in Q2 2025 to a low of $711000.0 in Q4 2023.
• The 5-year median for Other Non-Current Assets is $1.2 million (2025), against an average of $1.1 million.
• Across the five-year window, Other Non-Current Assets retreated 21.18% in 2023 and soared 63.29% in 2024, its largest moves.
• ADC Therapeutics' Other Non-Current Assets stood at $902000.0 in 2022, then decreased by 21.18% to $711000.0 in 2023, then jumped by 63.29% to $1.2 million in 2024, then grew by 4.82% to $1.2 million in 2025, then increased by 2.38% to $1.2 million in 2026.
• The last three Other Non-Current Assets figures came in at $1.2 million (Q1 2026), $1.2 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.